Filarial Diseases Translation


  • Target disease: Filarial diseases
  • Main partners (since project start): Abbvie, USA; AWOL, UK.
  • Start date: March 2015
  • Funding (since project start): Bill & Melinda Gates Foundation, USA.


Overall Objective:

  • Develop TylAMac as an anti-Wolbachia therapy and assess its macrofilaricidal efficacy.


ABBV-4083 is a derivative of Tylosin, a veterinary antibiotic which targets the worm-symbiont Wolbachia bacterium. The compound is currently in full pre-clinical development for treatment of filarial diseases. ABBV-4083 is orally available, induces a robust anti-Wolbachia effect in several in vivo models, demonstrates clear superiority over doxycycline, and is effective after a shorter dosing regimen. Preliminary safety and toxicology profiling of this compounds suggests a favourable safety profile. Upon completion of enabling toxicology studies, expected in 2017, and the development of an oral formulation, a Phase I study in healthy human volunteers will be performed in 2017. The aim will be to assess the safety, tolerability and the pharmacokinetics of ABBV-4083.


Last update: February 2017